Table 2. Demographic, clinical, and laboratory data for patients with and without NASH.
| NASH | no NASH | P-value | Test | |
| N | 22 | 15 | ||
| Fibrosis (any) | 22 (100%) | 10 (67%) | 0.015 | Chi |
| Advanced fibrosis | 3 (14%) | 3 (20%) | 0.667 | FE |
| Diabetes | 8 (36%) | 5 (33%) | 0.872 | Chi |
| Female | 16 (73%) | 9 (60%) | 0.647 | Chi |
| Caucasian | 19 (86%) | 12 (80%) | 0.951 | Chi |
| Age | 49±9 | 47±11 | 0.596 | 2T |
| BMI | 49±11 | 46±9 | 0.421 | MW |
| Hyperlipidemia | 12 (54%) | 11 (73%) | 0.417 | Chi |
| Hypertension | 15 (68%) | 11 (73%) | 0.801 | Chi |
| AST (U/L) | 23±6.4 | 22±7.4 | 0.760 | 2T |
| ALT (U/L) | 35±18 | 29±9 | 0.496 | MW |
| AST: ALT | 0.74±0.21 | 0.82±0.34 | 0.577 | MW |
| Albumin (g/dL) | 4.1±0.27 | 3.9±0.77 | 0.732 | MW |
| Bilirubin (total) (mg/dL) | 0.44±0.17 | 0.59±0.38 | 0.263 | MW |
| White blood cell count(103/uL) | 7.6±2.2 | 6.9±1.6 | 0.246 | MW |
| Platelet count (103/uL) | 274±78 | 270±69 | 0.845 | 2T |
| Hemoglobin (g/dL) | 13±1.1 | 13±1.7 | 0.878 | 2T |
| Glucose (mg/dL) | 116±43 | 104±32 | 0.556 | MW |
| Cholesterol (total) (mg/dL) | 187±30 | 190±41 | 0.808 | 2T |
| Triglycerides (mg/dL) | 179±144 | 174±83 | 0.458 | MW |
| HDL (mg/dL) | 47±9 | 51±11 | 0.182 | 2T |
| CCL-2 (pg/mL) | 464±118 | 486±218 | 0.902 | MW |
| sFasL (pg/mL) | 89±31 | 82±34 | 0.516 | MW |
| Portal fibrosis | 16 (73%) | 10 (67%) | 0.976 | Chi |
| Pericellular fibrosis | 12 (54%) | 0 (0%) | n/a |
Entries are counts for discrete measures (with percentage of group total given in parentheses) or mean ± S.D. for continuous measures. A p-value of ≤0.05 was considered significant. Significant results are shown in bold text. Chi = chi square test of homogeneity; FE = Fisher’s exact test; MW = Mann-Whitney U test; 2T = two-sample t-test (2-tailed).